• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Everolimus EP Impurity B

Everolimus EP Impurity B

Product ID E846184
Cas No. 1062122-63-7
Purity ≥96% (mix of E/Z)
Product Unit SizeCostQuantityStock
5 mg $799.40 In stock
10 mg $1,488.40 In stock
25 mg $3,031.90 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Everolimus EP Impurity B is an impurity of Everolimus. Everolimus is an inhibitor of mammalian target of rapamycin 1 (mTOR1) that is used clinically for its immunosuppressive activity in renal transplant recipients and is currently in clinical trials exploring its anticancer chemotherapeutic activity. In nasopharyngeal carcinoma cells, everolimus induces apoptosis and autophagy, inhibiting cell growth. In esophageal cancer cells, everolimus decreases expression of mTOR targets p70S6K and S6, increasing cell damage and decreasing cell proliferation. In animal models of experimental autoimmune uveoretinitis (EAU), everolimus decreases levels of Th1, Th2, and Th17 cytokines and increases levels of Treg cells, attenuating disease pathology. Additionally, everolimus exhibits nephroprotective benefit at low doses, decreasing adriamycin-induced proteinuria and improving renal function in animal models of nephrotic syndrome.

Product Info

Cas No.

1062122-63-7

Purity

≥96% (mix of E/Z)

Formula

C53H83NO14

Formula Wt.

958.2

Chemical Name

(2S)-1-[[(2R,3R,6S)-2-hydroxy-6-[(2S,3E,5E,7E,9S,11R,13R,14R,15E,17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxodocosa-3,5,7,15,19-pentaen-1-yl]-3-methyloxan-2-yl](oxo)acetyl]piperidine-2-carboxylic acid

IUPAC Name

(2S)-1-[2-[(2R,3R,6S)-2-hydroxy-6-[(2S,3E,5E,7E,9S,11R,13R,14R,15E,17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxodocosa-3,5,7,15,19-pentaenyl]-3-methyloxan-2-yl]-2-oxoacetyl]piperidine-2-carboxylic acid

Synonym

Everolimus 19-Ene Open-Ring Impurity ; seco Everolimus ; (19E/Z)-seco-[4-O-(2-Hydroxyethyl)] Rapamycin

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

Info Sheet

E846184 Info Sheet PDF

References

Sendur MA, Zengin N, Aksoy S, et al. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin. 2014 Jan;30(1):75-87. PMID: 24050600.

Cai Y, Xia Q, Su Q, et al. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. Int J Mol Med. 2013 Apr;31(4):904-12. PMID: 23426850.

Hennig M, Bauer D, Wasmuth S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res. 2012 Dec;105:43-52. PMID: 23059401.

Ramadan R, Faour D, Awad H, et al. Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol Dial Transplant. 2012 Jun;27(6):2231-41. PMID: 22036940.

Wang ZG, Fukazawa T, Nishikawa T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep. 2010 Apr;23(4):1167-72. PMID: 20204306.

Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001 Aug;7(4):242-50. PMID: 11571421.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C9710

    Cyclopamine

    Steroidal jerveratrum alkaloid found in Veratru...

    ≥98%
  • F5976

    Fotemustine

    Chloroethylnitrosourea, DNA alkylator and cross...

    ≥98%
  • A5217

    trans-Anethole

    Phenylpropene derivative found in essential oil...

    ≥98%
  • V1872

    Vesicular Stomatitis Virus Peptide

    Peptide fragment of VSV; LDLR agonist.

    ≥95%
  • M1845

    Melitracen Hydrochloride

    Tricyclic antidepressant; potential D1/2 antago...

    ≥99%
  • G3357

    Ginkgolide C

    Diterpene lactone found in Ginkgo; GABA-A, α-1...

    ≥98%
  • T3185

    Thymidine

    Pyrimidine nucleoside base, pairs with adenosin...

    ≥98%
  • T342710

    Tirzepatide

    GLP-1/GIP receptor co-agonist

    ≥98%
  • I8618

    Ivermectin

    Avermectin; glu-gated Cl- channel activator, Gl...

    ≥95%
  • T1298

    TDZD-8

    GSK-3β inhibitor.

    ≥98%
  • G2873

    Growth Hormone Releasing Factor, sheep

    Endogenous peptide hormone, involved in growth ...

    ≥95%
  • R8179

    Rutaecarpine, synthetic

    Found in Evodia rutaecarpa; potential cAMP, 3β...

    ≥98%
  • K0652

    Kb NB 142-70

    PKD inhibitor.

    ≥98%
  • I7074

    Irsogladine Maleate

    NSAID; COX-1/2 and PDE inhibitor.

    ≥98%
  • P1760

    Peptide T

    Peptide fragment of HIV-1 gp120.

    ≥98%
  • V182685

    Verdinexor

    CRM1/XPO1 inhibitor.

    ≥99%
  • M1749

    Memantine Hydrochloride

    D2 agonist, NMDA, 5-HT3, α7 nAChR antagonist.<...

    ≥97%
  • E325125

    EIDD-2801

    COVID-19 research

    ≥98%
  • S1606

    Secretin, porcine

    Endogenous peptide hormone, involved in water h...

    ≥95%
  • B4974

    BMS-777607

    MET and Ron inhibitor.

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only